News
2021.10.25
Lim Chong-yoon, CEO of Hanmi Science (Courtesy of Hanmi Pharm)
Lim Chong-yoon, CEO of Hanmi Science, was appointed as a director of Oxford Vacmedix, a biopharmaceutical company based in the UK.
According to an announcement made by the British biopharma company, Lim was appointed as a director representing Cancer ROP. Oxford Vacmedix is a biopharmaceutical company specializing in developing cancer vaccines spun out from the University of Oxford in 2012. Cancer ROP acquired 42.89% of the shares in 2018, becoming the largest shareholder.
William Finch, CEO of Oxford Vacmedix, said, “CEO Lim, who was appointed CEO of Hanmi Pharm in 2009, led the management of Hanmi Pharmaceutical and led to high growth by licensing a number of new drug candidates to global pharmaceutical companies. He is currently CEO of Hanmi Science, and in 2019, he was named [President] of the Korea Biotechnology Association,” and raised anticipation for the role he will play as a businessman with expertise in R&D management.
The CEO of Oxford Vacmedix also said, “I am delighted to welcome Mr. Lim to the Board of Oxford Vacmedix at this critical time, as we advance our lead cancer vaccine, OVM-200, into Phase 1. Mr. Lim has extensive experience with company development and financing with many years of working in biotech in the US, China and South Korea with particular expertise in immunology and drug development.”
He also explained that in CEO Lim’s role on the board “he will be able to support OVM as we move forward to achieve our vision of advancing effective vaccines that address the unmet medical needs of cancer patients.”
He then stated that CEO Lim’s visit to the UK was also to discuss a joint R&D project with Oxford Vacmedix and a partner that could not be revealed at this time.
Lim Chong-yoon, CEO of Hanmi Science, said, “Oxford Vacmedics’ ROP technology will enable safe and effective treatments to help people with cancer live longer while enjoy a higher quality of life, and we hope to support the development of vaccines for clinical applications. [...] The technology can be applied to vaccine development for infectious diseases, and it will be possible to achieve further growth by attracting investment in Series B.”
Source: Daily Hankook